Zoetis Inc (ZTS) Shares Bought by FDx Advisors Inc.
FDx Advisors Inc. lifted its position in shares of Zoetis Inc (NYSE:ZTS) by 23.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 67,741 shares of the company’s stock after buying an additional 13,053 shares during the period. FDx Advisors Inc.’s holdings in Zoetis were worth $4,880,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $108,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the third quarter valued at approximately $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares during the period. Shine Investment Advisory Services Inc. increased its stake in shares of Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after acquiring an additional 1,040 shares during the period. Finally, Advisory Services Network LLC increased its stake in shares of Zoetis by 42.4% during the fourth quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock valued at $175,000 after acquiring an additional 721 shares during the period. Hedge funds and other institutional investors own 91.53% of the company’s stock.
In related news, insider Heidi C. Chen sold 37,453 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total transaction of $3,034,442.06. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 35,663 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares in the company, valued at $4,044,437.38. The disclosure for this sale can be found here. Insiders have sold 97,001 shares of company stock valued at $7,882,428 in the last 90 days. 0.31% of the stock is currently owned by corporate insiders.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the prior year, the company earned $0.47 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. equities analysts forecast that Zoetis Inc will post 3.03 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is 28.57%.
Several research analysts have issued reports on the stock. Jefferies Group set a $97.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, February 26th. Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price objective for the company in a research note on Thursday, January 4th. Piper Jaffray Companies set a $88.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, February 16th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a research note on Monday, January 8th. Finally, Deutsche Bank raised their price target on shares of Zoetis from $76.00 to $78.00 and gave the company a “hold” rating in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and a consensus target price of $80.28.
WARNING: This piece of content was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.mareainformativa.com/2018/03/15/zoetis-inc-zts-shares-bought-by-fdx-advisors-inc-updated-updated-updated.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.